journal article·2025-04Open access

Biomineralization of Copper‐Celastrol Nanohybrids for Synergistic Antitumor Therapy

Yifan Li, Na Wang, Hanrong Li, Xingyun Zhang, Liuxian Meng, Yingjie Yu, Shihui Wang, Li Deng

Small· Volume 21· Issue 17

Abstract

Abstract The therapeutic potential of celastrol (Cel) in cancer treatment has been constrained by its intrinsic hydrophobicity and the lack of efficient delivery systems. Herein, a biomineralization‐based strategy is introduced to construct hybrid nanoparticles (Cel‐TA‐Cu NP) via Cel‐Cu2⁺ coordination, followed by TA‐Cu2⁺ crosslinking. Biomineralization, a nature‐inspired process facilitating the controlled assembly of inorganic–organic structures, enables Cel to form coordination complexes with Cu2⁺, which subsequently serve as nucleation sites for tannic acid‐mediated copper mineralization. Unlike conventional nanocarriers, this approach exploits the intrinsic metal‐binding capacity of Cel to induce spontaneous mineralization, where Cu2⁺ serves both as a coordination center for drug encapsulation and as a therapeutic agent for chemodynamic therapy (CDT). The pH‐responsive dissociation of metal‐phenolic coordination ensures tumor‐specific drug release, while the biomineralization process inherently enhances aqueous stability and bioavailability. Moreover, the rational design of Cel‐TA‐Cu NP enables a synergistic anticancer effect by simultaneously triggering apoptotic signaling pathways and amplifying oxidative stress‐induced cytotoxicity. Overall, this biomineralization‐based nanoplatform not only overcomes the inherent limitations of Cel but also integrates CDT to markedly enhance therapeutic efficacy, providing a promising avenue for advanced cancer treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Natural Compounds in Disease Treatment · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Life Science and Technology Beijing University of Chemical Technology Beijing 100029 China

Immunology and Oncology Center ICE Bioscience Beijing 100176 China

State Key Laboratory of Organic‐Inorganic Composites Beijing Laboratory of Biomedical Materials Beijing University of Chemical Technology Beijing 100029 China

The People's Hospital of Gaozhou National Drug Clinical Trial Institution Gaozhou 525200 China

Funding

Natural Science Foundation of Beijing Municipality · National Natural Science Foundation of China

References (52)

Show source-provided references
1. 10.1016/j.cell.2007.08.02110.1016/j.cell.2007.08.021 ↗
2. 10.1007/s10495-011-0629-610.1007/s10495-011-0629-6 ↗
3. 10.1016/j.cell.2015.05.01110.1016/j.cell.2015.05.011 ↗
4. 10.1016/j.canlet.2010.07.01510.1016/j.canlet.2010.07.015 ↗
5. 10.1016/j.biopha.2023.11488210.1016/j.biopha.2023.114882 ↗
6. 10.1002/smll.20210180410.1002/smll.202101804 ↗
7. 10.1039/C9TB00155G10.1039/C9TB00155G ↗
8. 10.1016/j.mtadv.2022.10027610.1016/j.mtadv.2022.100276 ↗
9. 10.1016/j.cej.2019.12322810.1016/j.cej.2019.123228 ↗
10. 10.1038/s41467-017-00834-810.1038/s41467-017-00834-8 ↗
11. 10.1039/D1BM00639H10.1039/D1BM00639H ↗
12. 10.1039/C8NR02700E10.1039/C8NR02700E ↗
13. 10.1016/j.nantod.2022.10145910.1016/j.nantod.2022.101459 ↗
14. 10.1002/adfm.20220879710.1002/adfm.202208797 ↗
15. 10.1002/anie.20180566410.1002/anie.201805664 ↗
16. 10.1039/C7CS00471K10.1039/C7CS00471K ↗
17. 10.1039/D3NR02000B10.1039/D3NR02000B ↗
18. 10.1002/adma.20180827810.1002/adma.201808278 ↗
19. 10.1021/jacs.9b1287310.1021/jacs.9b12873 ↗
20. 10.1002/smtd.20220037910.1002/smtd.202200379 ↗
21. 10.1038/s41467-024-53646-y10.1038/s41467-024-53646-y ↗
22. 10.1039/B312445B10.1039/B312445B ↗
23. 10.1002/anie.20151003110.1002/anie.201510031 ↗
24. 10.1021/jacs.8b0871410.1021/jacs.8b08714 ↗
25. 10.1002/anie.20210174410.1002/anie.202101744 ↗
26. 10.1039/D2SC01379G10.1039/D2SC01379G ↗
27. 10.1016/j.cej.2021.12888010.1016/j.cej.2021.128880 ↗
28. 10.1016/j.biomaterials.2021.12111010.1016/j.biomaterials.2021.121110 ↗
29. 10.1016/j.msec.2018.10.09210.1016/j.msec.2018.10.092 ↗
30. 10.1002/adma.20231045610.1002/adma.202310456 ↗
31. 10.1126/science.abf052910.1126/science.abf0529 ↗
32. 10.1002/adma.20240497110.1002/adma.202404971 ↗
33. 10.1002/advs.20230938810.1002/advs.202309388 ↗
34. 10.1021/acsnano.9b0583610.1021/acsnano.9b05836 ↗
35. 10.1002/smll.20240753910.1002/smll.202407539 ↗
36. 10.1002/adma.20221087610.1002/adma.202210876 ↗
37. 10.1016/j.mtbio.2023.10069810.1016/j.mtbio.2023.100698 ↗
38. 10.1002/smll.20240644110.1002/smll.202406441 ↗
39. 10.1126/sciadv.abl965310.1126/sciadv.abl9653 ↗
40. 10.1039/C7SC03868B10.1039/C7SC03868B ↗
41. 10.1039/D4NR01536C10.1039/D4NR01536C ↗
42. 10.1039/D2NR07117G10.1039/D2NR07117G ↗
43. 10.1016/j.mtbio.2022.10043610.1016/j.mtbio.2022.100436 ↗
44. 10.1039/C9NR06691H10.1039/C9NR06691H ↗
45. 10.1002/adma.20211009410.1002/adma.202110094 ↗
46. 10.1021/acsnano.2c0591710.1021/acsnano.2c05917 ↗
47. 10.1016/j.mtbio.2023.10067010.1016/j.mtbio.2023.100670 ↗
48. 10.1002/smll.20220031610.1002/smll.202200316 ↗
49. 10.1007/s12672-023-00838-510.1007/s12672-023-00838-5 ↗
50. 10.7150/ijbs.9959210.7150/ijbs.99592 ↗
51. 10.1016/j.elspec.2019.06.01010.1016/j.elspec.2019.06.010 ↗
52. 10.1038/ncomms315710.1038/ncomms3157 ↗